IN2014CN02736A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02736A
IN2014CN02736A IN2736CHN2014A IN2014CN02736A IN 2014CN02736 A IN2014CN02736 A IN 2014CN02736A IN 2736CHN2014 A IN2736CHN2014 A IN 2736CHN2014A IN 2014CN02736 A IN2014CN02736 A IN 2014CN02736A
Authority
IN
India
Prior art keywords
compositions
methods compounds
symptom
animal
protein
Prior art date
Application number
Inventor
Susan M Freier
Sanjay Bhanot
Original Assignee
Isis Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Phamaceuticals Inc filed Critical Isis Phamaceuticals Inc
Publication of IN2014CN02736A publication Critical patent/IN2014CN02736A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Provided herein are methods compounds and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods compounds and compositions are useful to treat prevent delay or ameliorate metabolic disease for example diabetes or a symptom thereof.
IN2736CHN2014 2011-09-20 2012-09-20 IN2014CN02736A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161537007P 2011-09-20 2011-09-20
PCT/US2012/056249 WO2013043817A1 (en) 2011-09-20 2012-09-20 Antisense modulation of gcgr expression

Publications (1)

Publication Number Publication Date
IN2014CN02736A true IN2014CN02736A (en) 2015-07-03

Family

ID=47914848

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2736CHN2014 IN2014CN02736A (en) 2011-09-20 2012-09-20

Country Status (17)

Country Link
US (2) US8865674B2 (en)
EP (2) EP3401401B1 (en)
JP (2) JP6092226B2 (en)
KR (1) KR101840512B1 (en)
CN (2) CN108410868A (en)
AU (2) AU2012312433B2 (en)
BR (1) BR112014006587B1 (en)
CA (1) CA2849273C (en)
DK (1) DK2758533T3 (en)
ES (2) ES2796556T3 (en)
HK (1) HK1201070A1 (en)
IL (1) IL231560B (en)
IN (1) IN2014CN02736A (en)
MX (1) MX353322B (en)
NO (1) NO2925947T3 (en)
RU (1) RU2598709C2 (en)
WO (1) WO2013043817A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378533A1 (en) 2012-02-08 2014-12-25 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
DK3524680T3 (en) * 2013-05-01 2020-12-14 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
ES2812099T3 (en) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Compositions and methods for modulating growth hormone receptor expression
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
AR101449A1 (en) * 2014-08-04 2016-12-21 Miragen Therapeutics Inc MYH7B INHIBITORS AND USES OF THE SAME
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
WO2016141236A1 (en) * 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
JP6861641B2 (en) * 2015-04-02 2021-04-21 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ Methods for treating obesity and non-alcoholic steatohepatitis or non-alcoholic steatohepatitis with glucagon receptor antagonist antibodies
JP6833705B2 (en) * 2015-04-03 2021-02-24 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compounds and methods for regulating TMPRSS6 expression
CN108026529A (en) * 2015-09-30 2018-05-11 Ionis制药公司 Combination treatment
MA46089A (en) 2016-08-30 2019-07-10 Regeneron Pharma METHODS FOR TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
CN110177544A (en) 2016-11-29 2019-08-27 普尔泰克健康有限公司 For delivering the excretion body of therapeutic agent
CN108174843B (en) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 A kind of glucagon protective agent and its application
US20220162607A1 (en) * 2019-03-14 2022-05-26 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU1893192A (en) 1991-03-28 1992-11-02 University Of Tennessee Research Corporation, The Dna silver staining
JP3220180B2 (en) 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
JPH06508622A (en) 1991-06-18 1994-09-29 テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション Selective inhibition of leukocyte proliferation by bcr-ab1 antisense oligonucleotide
CA2112130C (en) 1991-06-27 1996-08-06 Cynthia A. Edwards Screening assay for the detection of dna-binding molecules
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5804383A (en) 1992-08-21 1998-09-08 The Regents Of The University Of California Method and assay for detection of the expression of allele-specific mutations by allele-specific in situ reverse transcriptase polymerase chain reaction
NZ255922A (en) 1992-08-28 1998-01-26 Zymogenetics Inc Glucagon receptor, dna constructs and host cells therefor
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US6410324B1 (en) 2001-04-27 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of tumor necrosis factor receptor 2 expression
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
JP3351476B2 (en) 1993-01-22 2002-11-25 三菱化学株式会社 Phospholipid derivatives and liposomes containing the same
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
ATE235549T1 (en) 1993-04-30 2003-04-15 Biognostik Ges ANTISENSE OLIGONUCLEOTIDES FOR TREATING IMMUNOSUPPRESSIVE EFFECTS OF TGF-BETA2
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612455A (en) 1994-07-05 1997-03-18 Tularik, Inc. Nuclear factors and binding assay
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
CA2253877A1 (en) 1997-03-07 1998-11-09 Mochida Pharmaceutical Co., Ltd. Antisense compounds to cd14
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
ES2221750T3 (en) 1998-07-23 2005-01-01 Gen-Probe Incorporated METHOD FOR DETECTION AND MEASUREMENT OF NUCLEIC ACIDS CUTED AND PACKED.
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US6692959B2 (en) 1998-11-25 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of IL-1 receptor-associated kinase-4 expression
US20030087854A1 (en) 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
ATE385237T1 (en) 1999-02-26 2008-02-15 Univ British Columbia ANTISENSE THERAPY FOR TRPM-2
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
ATE356824T1 (en) 1999-05-04 2007-04-15 Santaris Pharma As L-RIBO-LNA ANALOGUE
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US6284538B1 (en) * 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
EP1238071B1 (en) 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
US6869762B1 (en) * 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
US6602857B1 (en) * 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) * 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6770486B1 (en) 2000-02-08 2004-08-03 Isis Pharmaceuticals, Inc. Optimization of ligand affinity for RNA targets using mass spectrometry
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
WO2001092524A2 (en) 2000-05-26 2001-12-06 Aeomica, Inc. Myosin-like gene expressed in human heart and muscle
IL154473A0 (en) 2000-08-18 2003-09-17 Proskelia Regulator gene and system useful for the diagnosis and therapy of osteoporosis
WO2002027033A1 (en) 2000-09-29 2002-04-04 Isis Pharmaceuticals, Inc. Antisense modulation of mekk4 expression
WO2002045494A2 (en) * 2000-12-06 2002-06-13 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
JP2005504020A (en) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド Nuclease resistant chimeric oligonucleotide
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
DE60331831D1 (en) 2002-06-06 2010-05-06 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR MAKING MAIZE WITH INCREASED TRANSFORMABILITY
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
WO2004044133A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
MXPA05006604A (en) * 2002-12-19 2006-05-25 Alza Corp Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device.
US7750142B2 (en) * 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
JP4731324B2 (en) 2003-08-28 2011-07-20 武 今西 N-O bond cross-linked novel artificial nucleic acid
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
CA2550258A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US7341835B2 (en) * 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US7943754B2 (en) 2004-04-02 2011-05-17 Rosetta-Genomics Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
AU2005286738A1 (en) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
KR20080074101A (en) 2005-09-19 2008-08-12 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 Modulation of glucagon receptor expressionm
DE602007009487D1 (en) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
ES2366974T3 (en) * 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. COMPOUNDS AND PROCEDURES TO MODULATE THE EXPRESSION OF SGLT2.
AU2007253909B2 (en) * 2006-05-05 2012-08-09 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCCR
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
ES2388590T3 (en) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids with N-substituted aminomethylene bridge.
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
RU2010119775A (en) * 2007-11-09 2011-12-27 Айсис Фармасьютикалс,Инк. (Us) MODULATION OF EXPRESSION OF FACTOR 7
US8916531B2 (en) * 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
AT507215B1 (en) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg WEAR-RESISTANT MATERIAL
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Also Published As

Publication number Publication date
CN103814132A (en) 2014-05-21
DK2758533T3 (en) 2018-05-28
WO2013043817A8 (en) 2014-05-15
IL231560B (en) 2018-11-29
AU2012312433A1 (en) 2014-04-03
BR112014006587A8 (en) 2017-10-03
KR20140062083A (en) 2014-05-22
MX2014003492A (en) 2014-11-10
KR101840512B1 (en) 2018-03-20
JP6538736B2 (en) 2019-07-03
AU2017235886A1 (en) 2017-10-19
EP2758533B1 (en) 2018-04-11
EP3401401B1 (en) 2020-04-15
JP6092226B2 (en) 2017-03-08
EP2758533A4 (en) 2015-08-05
RU2014115215A (en) 2015-10-27
JP2014530004A (en) 2014-11-17
US8865674B2 (en) 2014-10-21
US9404114B2 (en) 2016-08-02
BR112014006587A2 (en) 2017-03-28
ES2796556T3 (en) 2020-11-27
MX353322B (en) 2018-01-05
NO2925947T3 (en) 2018-03-10
RU2598709C2 (en) 2016-09-27
ES2673721T3 (en) 2018-06-25
WO2013043817A1 (en) 2013-03-28
CN103814132B (en) 2018-06-05
IL231560A0 (en) 2014-04-30
CN108410868A (en) 2018-08-17
US20150099792A1 (en) 2015-04-09
NZ622398A (en) 2016-07-29
BR112014006587B1 (en) 2021-07-27
JP2017123849A (en) 2017-07-20
CA2849273C (en) 2020-07-21
HK1201070A1 (en) 2015-08-21
AU2017235886B2 (en) 2019-06-27
EP2758533A1 (en) 2014-07-30
AU2012312433B2 (en) 2017-07-06
CA2849273A1 (en) 2013-03-28
EP3401401A1 (en) 2018-11-14
US20130116301A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
IN2014CN03749A (en)
IN2014CN02736A (en)
IL266001B (en) Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
MX343559B (en) Modulation of transthyretin expression.
MY162715A (en) Modulation of apolipoprotein ciii (apociii) expression
MX353152B (en) Modulation of huntingtin expression.
UY34347A (en) DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS
MX2016008462A (en) Modulation of angiopoietin-like 3 expression.
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
EP2684167A4 (en) Compositions and methods useful for treating diseases
EP2701742A4 (en) Compositions and method for treating autoimmune diseases
WO2012174476A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
MX2011011839A (en) Prevention and treatment of nosema disease in bees.
EP2703396A4 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
MX367850B (en) PREVENTION and TREATMENT OF INFLAMMATORY CONDITIONS.
MX2014000142A (en) Use of anti-cd83 agonist antibodies for treating autoimmune diseases.
WO2012145254A9 (en) Methods of using inhibitors of rorϒt to treat disease
CL2014000557A1 (en) Improved antioxidant composition for animal feed and animal feed constituents; and method to improve said composition.
HK1205758A1 (en) Rnai agents to treat beta catenin related diseases
HK1259004A1 (en) Composition and method for treatment of diabetes
EA201500752A1 (en) METHOD OF TREATMENT OF DISEASES
EP2702997A4 (en) Method and composition for enhancing target cells uptake of therapeutic agents
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
EP2755671A4 (en) Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation
WO2011156673A3 (en) Modulation of phosphoenolpyruvate carboxykinase-mitochondrial (pepck-m) expression